What is the catalog number for Cenicriviroc?

The catalog number for Cenicriviroc is HY-14882.

What sizes are available for Cenicriviroc?

Cenicriviroc is available in the following size(s): 5 mg, 10 mM - 1 mL, 10 mg, 25 mg, 50 mg, 100 mg.

How many pack sizes does Cenicriviroc come in?

Cenicriviroc is available in 6 different pack sizes.

Is Cenicriviroc in stock?

Cenicriviroc is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Cenicriviroc?

Cenicriviroc is manufactured by QuantiMol.

What is the estimated delivery time for Cenicriviroc?

Estimated delivery time for Cenicriviroc is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for Cenicriviroc?

The safety data sheet for Cenicriviroc is available here: http://file.medchemexpress.com/batch_PDF/HY-14882/Cenicriviroc-SDS-MedChemExpress.pdf.

Cenicriviroc

Cenicriviroc (TAK-652) is an orally active, dual CCR2/CCR5 antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity[1].

Product Specifications

CAS Number

497223-25-3

Product Name Alternative

TAK-652; TBR-652

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

CCR; HIV

Type

Reference compound

Related Pathways

Anti-infection; GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-anti-virus

Field of Research

Infection; Endocrinology

Assay Protocol

https://www.medchemexpress.com/Cenicriviroc.html

Purity

99.51

Solubility

DMSO : 50 mg/mL (ultrasonic) |Ethanol : 2 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : < 0.1 mg/mL

Smiles

O=C(/C1=C/C2=CC(C3=CC=C(OCCOCCCC)C=C3)=CC=C2N(CC(C)C)CCC1)NC4=CC=C([S@](CC5=CN=CN5CCC)=O)C=C4

Molecular Formula

C41H52N4O4S

Molecular Weight

696.94

Precautions

H302, H315, H319, H335

References & Citations

[1]Lefebvre E, et al. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. PLoS One. 2016 Jun 27;11 (6) :e0158156|[2]Kuwata T, et al. Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies. Antimicrob Agents Chemother. 2015 Nov 2;60 (1) :437-5|[3]Visseaux B, et al. Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates. PLoS One. 2015 Aug 6;10 (8) :e0134904|[4]Lalezari J, et al. Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects. J Acquir Immune Defic Syndr. 2011 Jun 1;57 (2) :118-25.|[5]Baba M, et al. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob Agents Chemother. 2005 Nov;49 (11) :4584-91.